| 0.28698 -0.013 (-4.34%) | 12-11 15:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.47 | 1-year : | 0.6 |
| Resists | First : | 0.4 | Second : | 0.51 |
| Pivot price | 0.28  |
|||
| Supports | First : | 0.21 | Second : | 0.18 |
| MAs | MA(5) : | 0.28 |
MA(20) : | 0.31 |
| MA(100) : | 0.38 |
MA(250) : | 0.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15 |
D(3) : | 11.4 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 1.66 | Low : | 0.18 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BTCY ] has closed above bottom band by 46.5%. Bollinger Bands are 74% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.3 - 0.3 | 0.3 - 0.3 |
| Low: | 0.27 - 0.27 | 0.27 - 0.28 |
| Close: | 0.28 - 0.29 | 0.29 - 0.29 |
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Tue, 03 Dec 2024
Biotricity Achieves Positive Free Cash Flow Milestone - PR Newswire
Tue, 03 Dec 2024
Biotricity Achieves First-Ever Positive Free Cash Flow of $355K, Plans Product Expansion - StockTitan
Mon, 18 Nov 2024
Biotricity, Inc. (NASDAQ:BTCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sat, 16 Nov 2024
Biotricity Inc (BTCY) Q2 2025 Earnings Call Highlights: Milestone Achievements and Strategic Growth - Yahoo Finance
Wed, 13 Nov 2024
Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th - GlobeNewswire
Thu, 04 Apr 2024
Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 22 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 46.5 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 460 (K) |
| Shares Short P.Month | 503 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.38 |
| Profit Margin | -117.5 % |
| Operating Margin | -34.9 % |
| Return on Assets (ttm) | -82.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.54 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | -0.21 |
| Price to Sales | 0.52 |
| Price to Cash Flow | -1.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|